NA
YMAB

Neuburgh Advisers’s Y-mAbs Therapeutics YMAB Stock Holding History

Neuburgh Advisers’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$30K Sell
1,166
-440
-27% -$11.2K ﹤0.01% 865
2019
Q2 		$37K Sell
1,606
-1,100
-41% -$25.3K ﹤0.01% 873
2019
Q1 		$71K Hold
2,706
– – ﹤0.01% 827
2018
Q4 		$55K Sell
2,706
-3,036
-53% -$69.7K ﹤0.01% 824
2018
Q3 		$153K Buy
+5,742
New +$146K ﹤0.01% 751

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Neuburgh Advisers's YMAB Position: Q3 2019 in Review

Neuburgh Advisers reduced its Y-mAbs Therapeutics (YMAB) stake by 27% in Q3 2019, selling an estimated $11.2K and leaving 1,166 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #865.

Neuburgh Advisers first reported a position in YMAB in Q3 2018 and has held it in 5 quarters since. The position peaked at $153K in Q3 2018. 65 funds tracked by Wall St. Rank hold YMAB as of Q3 2019.

  • Neuburgh Advisers held 1,166 shares of Y-mAbs Therapeutics worth $30K as of Q3 2019.
  • Neuburgh Advisers sold 440 Y-mAbs Therapeutics shares in Q3 2019, an estimated $11.2K.
  • Y-mAbs Therapeutics made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #865 holding.
  • Neuburgh Advisers first reported a position in Y-mAbs Therapeutics in Q3 2018 and has held it in 5 quarters since.
  • Neuburgh Advisers's Y-mAbs Therapeutics position peaked at $153K in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.